Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab in Alopecia Totalis/Universalis
NCT00746980Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Aug 2008
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of efalizumab in alopecia totalis (AT), alopecia universalis (AU), alopecia areata, sponsored by Northwestern University. Planned start Aug 2008; status: withdrawn.
02
Drugs
efalizumab
03
Conditions
alopecia totalis (AT)alopecia universalis (AU)alopecia areata
Beyond the preview
Go deeper on NCT00746980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00746980.